203 related articles for article (PubMed ID: 12891225)
1. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe.
Majumdar AK; McCrea JB; Panebianco DL; Hesney M; Dru J; Constanzer M; Goldberg MR; Murphy G; Gottesdiener KM; Lines CR; Petty KJ; Blum RA
Clin Pharmacol Ther; 2003 Aug; 74(2):150-6. PubMed ID: 12891225
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity.
Shadle CR; Lee Y; Majumdar AK; Petty KJ; Gargano C; Bradstreet TE; Evans JK; Blum RA
J Clin Pharmacol; 2004 Mar; 44(3):215-23. PubMed ID: 14973304
[TBL] [Abstract][Full Text] [Related]
3. Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant.
Stoch SA; Gargano C; Valentine J; Braun MP; Murphy MG; Fedgchin M; Majumdar A; Pequignot E; Gottesdiener KM; Petty KJ; Panebianco D; Dean D; Kraft WK; Greenberg HE
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1313-21. PubMed ID: 20734049
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects.
Marbury TC; Ngo PL; Shadle CR; Jin B; Panebianco D; Caro L; Valentine J; Murphy G
J Clin Pharmacol; 2011 Dec; 51(12):1712-20. PubMed ID: 21209230
[TBL] [Abstract][Full Text] [Related]
5. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
6. Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.
Hsyu PH; Pignataro DS; Matschke K
Eur J Clin Pharmacol; 2017 Jan; 73(1):49-56. PubMed ID: 27718000
[TBL] [Abstract][Full Text] [Related]
7. Effect of aprepitant on the pharmacokinetics of intravenous midazolam.
Majumdar AK; Yan KX; Selverian DV; Barlas S; Constanzer M; Dru J; McCrea JB; Ahmed T; Frick GS; Kraft WK; Petty KJ; Greenberg HE
J Clin Pharmacol; 2007 Jun; 47(6):744-50. PubMed ID: 17463213
[TBL] [Abstract][Full Text] [Related]
8. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone.
McCrea JB; Majumdar AK; Goldberg MR; Iwamoto M; Gargano C; Panebianco DL; Hesney M; Lines CR; Petty KJ; Deutsch PJ; Murphy MG; Gottesdiener KM; Goldwater DR; Blum RA
Clin Pharmacol Ther; 2003 Jul; 74(1):17-24. PubMed ID: 12844131
[TBL] [Abstract][Full Text] [Related]
9. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects.
Blum RA; Majumdar A; McCrea J; Busillo J; Orlowski LH; Panebianco D; Hesney M; Petty KJ; Goldberg MR; Murphy MG; Gottesdiener KM; Hustad CM; Lates C; Kraft WK; Van Buren S; Waldman SA; Greenberg HE
Clin Ther; 2003 May; 25(5):1407-19. PubMed ID: 12867217
[TBL] [Abstract][Full Text] [Related]
10. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice.
Veronese ML; Gillen LP; Burke JP; Dorval EP; Hauck WW; Pequignot E; Waldman SA; Greenberg HE
J Clin Pharmacol; 2003 Aug; 43(8):831-9. PubMed ID: 12953340
[TBL] [Abstract][Full Text] [Related]
11. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.
Schmitt C; Hofmann C; Riek M; Patel A; Zwanziger E
Pharmacotherapy; 2009 Oct; 29(10):1175-81. PubMed ID: 19792991
[TBL] [Abstract][Full Text] [Related]
12. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
Pentikis HS; Connolly M; Trapnell CB; Forbes WP; Bettenhausen DK
Pharmacotherapy; 2007 Oct; 27(10):1361-9. PubMed ID: 17896891
[TBL] [Abstract][Full Text] [Related]
13. An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.
Tomkinson HK; Kemp JV; Wollseifen T; Morris T; Oliver SD
Clin Ther; 2010 Jul; 32(7):1372-86. PubMed ID: 20678684
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects.
Wang X; Wang J; Arora S; Hughes L; Christensen J; Lu S; Zhang ZY
J Clin Pharmacol; 2019 Apr; 59(4):488-499. PubMed ID: 30422319
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.
Hoch M; Hoever P; Alessi F; Theodor R; Dingemanse J
Eur J Clin Pharmacol; 2013 Mar; 69(3):523-32. PubMed ID: 22990330
[TBL] [Abstract][Full Text] [Related]
16. Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
Zhang D; Mita M; Shapiro GI; Poon J; Small K; Tzontcheva A; Kantesaria B; Zhu Y; Bannerji R; Statkevich P
Cancer Chemother Pharmacol; 2012 Dec; 70(6):891-8. PubMed ID: 23053255
[TBL] [Abstract][Full Text] [Related]
17. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.
de Jonge ME; Huitema AD; Holtkamp MJ; van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2005 Oct; 56(4):370-8. PubMed ID: 15838656
[TBL] [Abstract][Full Text] [Related]
18. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation.
Backman JT; Mäenpää J; Belle DJ; Wrighton SA; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Apr; 67(4):382-90. PubMed ID: 10801247
[TBL] [Abstract][Full Text] [Related]
19. Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers.
Li SX; Pequignot E; Panebianco D; Lupinacci P; Majumdar A; Rosen L; Ahmed T; Royalty JE; Rushmore TH; Murphy MG; Petty KJ
J Clin Pharmacol; 2006 Jul; 46(7):792-801. PubMed ID: 16809805
[TBL] [Abstract][Full Text] [Related]
20. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S
J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
